Does Duloxetine Increase LES Pressure and Reduce TLESRs?
There is no evidence that duloxetine increases lower esophageal sphincter (LES) pressure or reduces transient lower esophageal sphincter relaxations (TLESRs).
Evidence Review
After systematic review of the provided evidence, including FDA drug labels 1, recent clinical guidelines 2, 3, and research studies 4, 5, 6, 7, 8, none of these sources mention any effect of duloxetine on LES function or TLESRs.
What the Evidence Shows
The FDA labeling for duloxetine extensively details its mechanism of action as a serotonin-norepinephrine reuptake inhibitor (SNRI), adverse effects, drug interactions, and clinical uses 1. The approved indications include major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain—but no gastrointestinal motility effects are described.
The AGA guidelines on GERD management 2, 3 discuss various therapeutic approaches including:
- PPI therapy optimization
- Upper esophageal sphincter compression devices
- Surgical interventions
- The role of transient LES relaxations in reflux pathophysiology
However, duloxetine is not mentioned as a treatment option for GERD or as having any effect on esophageal sphincter function.
Relevant Pharmacological Context
One study examined medications that relax the LES (benzodiazepines, calcium channel blockers, nitrates, β2 agonists, xanthines) and their association with esophageal cancer risk 8. Duloxetine was not included in this analysis, suggesting it is not recognized as affecting LES tone in either direction.
Clinical Implications
- Duloxetine should not be prescribed with the expectation of improving GERD symptoms through LES mechanisms
- If a patient on duloxetine has GERD, standard GERD management with PPIs and lifestyle modifications should be followed 2, 3
- The absence of documented LES effects means duloxetine is unlikely to worsen or improve reflux through this mechanism